• 1
    Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990; 29: 1858.
  • 2
    Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 22343.
  • 3
    Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 48190.
  • 4
    Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erytheniatosus (SLE): lessons from the past as we proceed to the future – the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008; 17: 43742.
  • 5
    Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010; 13: 311.
  • 6
    Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009; 10: 2637.
  • 7
    Dörner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 46475.
  • 8
    Ahmed S, Anolik JH. B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36: 10930.
  • 9
    Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus. An update. BioDrugs 2008; 22: 23949.
  • 10
    Arce E, Jackson DG, Gill MA, Bennet LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemiclupus erythematosus. J Immunol 2001; 167: 23619.
  • 11
    Dőrner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemie autoimmune diseases. Ther Clin Risk Manag 2007; 3: 9539.
  • 12
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliot G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cessano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003; 9: 3982s90s.
  • 13
    Mandik-Nayak L, Ridge N, Fields M, Park AY, Erikson J. Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol 2008; 20: 17.
  • 14
    Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008; 28: 1828.
  • 15
    Chan OT, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 519.
  • 16
    Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J Exp Med 1999; 189: 163948.
  • 17
    Chan OT, Madaio EP, Shlomchik MJ. The central and multiple roles of B-cells in lupus pathogenesis. Immunol Rev 1999; 169: 10721.
  • 18
    Looney RJ, Anolik J, Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010; 20: 110.
  • 19
    Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 206373.
  • 20
    Folzenlogen D, Hofer MF, Leung DY, Freed JH, Newell MK. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 1997; 83: 199204.
  • 21
    Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839.
  • 22
    Dörner T, Heimbächer C, Farner NL, Lipsky PE. Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythematosus. Clin Immunol 1999; 92: 18896.
  • 23
    Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 82335.
  • 24
    Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol 2005; 17: 2907.
  • 25
    Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005; 88: 150.
  • 26
    Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B- cell receptor signaling. Curr Biol 1997; 7: 13343.
  • 27
    Nadler MJ, McLean PA, Neel BG, Wortis HH. B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. J Immunol 1997; 159: 423343.
  • 28
    Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD, Perlmutter RM, Law C-L, Clark EA. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996; 384: 6347.
  • 29
    Eisenberg E. Targeting B cells in systemic lupus erythematosus: not just déjá vu all over again. Arthritis Res Ther 2006; 8: 108.
  • 30
    O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999; 189: 130713.
  • 31
    Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F, Parkhouse RM, O'Keefe TL, Neuberger MS, Izui S, Reiniger L. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000; 165: 298796.
  • 32
    Hatta Y, Tsuchiya N, Matsushita M, Shiota M, Hagiwara K, Tokunaga K. Identification of the gene variations in human CD22. Immunogenetics 1999; 49: 2806.
  • 33
    Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394403.
  • 34
    Dőrner T, Kaufmann J, Wegener WA, Teoh W, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74. (doi: 10.1186/ar1942).
  • 35
    McCluskey G, McKnight AJ, Brown DT. The ability of epratuzumab to induce cell death in primary human B cells [SAT0105]. Ann Rheum Dis 2008; 67 (Suppl. II): 469.
  • 36
    Carnahan J, Stein R, Zhengxing Q, Hess K, Cesano A, Hansen HJ, Goldenberg DM. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007; 44: 133141.
  • 37
    Jacobi AM, Goldenberg DM, Hiepe F. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67: 4507.
  • 38
    Leonard JP, Coleman M, Matthews JC, Chadburn A, Wegener WA, Hansen HJ, Ziccardi H, Kapushoc H, Gayko U, Cesano A, Fields SZ, Goldenberg DM. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL) [abstr]. Blood 2002; 100: 358A.
  • 39
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 30519.
  • 40
    Steinfeld SD, Tant L, Burmester GR, Teoh NKW, Wegener WA, Goldenberg DM, Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8: R129. (doi: 10.1186/ar2018).
  • 41
    Petri M, Hobbs K, Gordon C, Strand V, Wallace D, Kelley L, Wegener W, Barry A, Hopkin J. Randomized controlled trials (RCTS) of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares [OP-0016]. Ann Rheum Dis 2008; 67 (Suppl. II): 53.
  • 42
    Wallace D, Hobbs K, Houssiau F, Strand V, Tak P, Wegener W, Kelley L, Barry A. Randomized controlled trials of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients [THU0238]. Ann Rheum Dis 2008; 67 (Suppl. II): 212.
  • 43
    Strand V, Gordon C, Kalunian K, Coteur G, Barry A, Keininger D, Wegener W, Petri M. Randomized controlled trials (RCTS) of epratuzumab (anti-CD22 mAb targeting B-cells) show meaningful improvements in health related quality of life (HRQOL) in SLE patients (pts) with high disease activity and low baseline self-report measures [THU0239]. Ann Rheum Dis 2008; 67 (Suppl. II): 212.
  • 44
    Available at (last accessed 28 December 2009).
  • 45
    Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 22233.
  • 46
    Rudnicka L, Olszewska M, Kardynal A. Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al. Arthritis Rheum 2010; 62: 2566.
  • 47
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Czesano A, Woldenberg DM. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10: 532734.
  • 48
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 25809.
  • 49
    Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol 2006; 121: 112.
  • 50
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B-cells in-vivo by a chimeric mouse-human monoclonal-antibody to CD20. Blood 1994; 83: 43545.
  • 51
    Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 504451.
  • 52
    Strauss SJ, Morschhauser F, Gramatzki M, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer D, Teoh N, Wegener WA, Goldenberg DM, Horak ID, Lister TA. The Follicular Lymphoma International Prognostic Index (FLIPI) can be a useful prognostic indicator for patients with follicular lymphoma treated with combination of rituximab and epratuzumab. Blood 2005; 106: Abstract #4796.
  • 53
    Hernandez-Ilizaliturri F, Gada P, Repasky E, Czuczman M. Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined deficiency (SCID) mouse model [abstr]. Blood 2002; 100: 591.
  • 54
    Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non- Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 286878.
  • 55
    Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008; 9: 120615.
  • 56
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 116878.
  • 57
    Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 414250.
  • 58
    Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 29136.
  • 59
    Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 71927.
  • 60
    Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 32518.
  • 61
    Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B, LJP 394 Investigator Consortium. LJP394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 44254.